Alto Neuroscience Inc.

Day range

$21.70 – $22.26

Open

$22.17

Prev close

$21.97

Volume

550.06K

Market cap

$862.15M

Shares out

39.24M

P/E

—

P/S

—

P/B

3.93

P/FCF

—

ROE

-38.4%

ROA

-33.2%

Debt/Equity

0.09

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeAug 27, 2026

  In connection with Mr. Smith's promotion to President and Chief Financial Officer, on the Effective Date, the Company entered into a promotion and retention agreement (the "Promotion and Retention Agreement") with Mr. Smith. Pursuant to the Promotion and Retention Agreement, the Company has agreed to pay Mr. Smith a cash retention payment (the "Retention Payment") which shall be paid as follows: (1) $3,000,000 payable within ten days of the Effective Date and (2) $3,000,000 payable on the twelve-month anniversary of the Effective Date.

• Underwriting agreementJul 14, 2026

  On July 13, 2026, Alto Neuroscience, Inc. entered into an underwriting agreement (the 'Underwriting Agreement') with BofA Securities, Inc., as representative of the several underwriters set forth therein (collectively, the 'Underwriters'), to issue and sell 3,776,436 shares of common stock. BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C., and Robert W. Baird & Co. Incorporated are acting as the joint book-running managers for the Offering.

• Preliminary resultsJul 13, 2026

  Based upon preliminary estimates and information available to the Company, it estimates that its cash, cash equivalents and restricted cash were approximately $244.2 million as of June 30, 2026. This amount has not been audited, reviewed, or compiled by the Company's independent registered public accounting firm.

• Executive compensation changeMay 28, 2026

  Dr. Miller will be paid a $40,000 annual cash retainer for his service on the Board, plus a $5,000 annual cash retainer for his service on the NCGC, plus additional amounts for service on any additional committee(s) to which he may be appointed, paid in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred and pro-rated based on the number of actual days served by him during such quarter.

• Clinical trial resultsApr 1, 2026

  Alto Neuroscience, Inc. issued a press release entitled 'Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements.'

Days to cover

6.5

Short interest

4.66M

Avg volume

718.19K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Here's Why You Should Add ANRO Stock to Your Portfolio Now
  positiveZacks Investment Research· Oct 14, 2026
• Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
  positiveBenzinga· Feb 26, 2026
• ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
  negativeGlobeNewswire Inc.· Oct 7, 2025
• Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
  negativeGlobeNewswire Inc.· Sep 19, 2025
• ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
  negativeGlobeNewswire Inc.· Sep 19, 2025